It is recommended that where possible, a tumour tissue sample containing superficial tumour rather than deeply invasive tumour or tumour from a metastatic site should be used for p16 IHC, to increase the likelihood of detecting p16 overexpression, as it may be lost during tumour progression. This evidence concerns the gene CDKN2A and neoplasm.